Micro-Tech Endoscopy Announces Expansion of their SureClip® Portfolio: The Lockado Hemostasis Clip

Micro-Tech Endoscopy USA recently announced an expansion of its SureClip portfolio – the Lockado Hemostasis Clip. “Lockado’s improved clamping function means that the clip can apply superior closure and retention force to the opposing tissue, and lock it in place,” explained Chris Li, President of Micro-Tech Endoscopy USA. “Additionally, because we added opposing atraumatic teeth in the arms of the clip, customers will appreciate a more secure grip for reliable tissue management.”

Micro-Tech Endoscopy USA reports SureClip became popular with Micro-Tech customers due to its ease of use and ergonomic design. These same benefits continue with Lockado.

The convenient thumb ring allows for comfortable deployment while the rotation grip provides 360-degrees of controlled rotation. Combined, the Lockado offers physicians accuracy, reliability, and added confidence.

Since 2000, Micro-Tech has been focused on creating top-quality products for endoscopic diagnosis and therapeutic medical devices that allow physicians to provide the highest level of care. By partnering with doctors dedicated to innovation, we are committed to bringing better devices to market, with unprecedented speed, at an economical price, and without the burden of contracts. We do not compromise on quality and do not believe our customers should either.

Micro-Tech Endoscopy has operations in America, Asia, and Europe and leverages this global reach to refine the products we provide to our partners. Our team has a wealth of experience in the field and an in-depth understanding of both product and use cases.

With the health care industry transforming rapidly, we dedicate ourselves to set the pace as a disruptor. At Micro-Tech, we are more than a medical technology company – we are building a community of healthcare innovators and making health care more value-driven.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version